Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 558

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 558
---
, investor relations activities and other administrative and professional services. We also expect to allocate additional expenses relating to administrative, finance, legal, and other corporate functions to adapt to the changes above and the anticipated growth of our business. 334

Results of Operations The following tables summarize our results of operations for the three months ended March 31, 2025 and 2024 and the years ended December 31, 2024 and 2023, together with the changes in those items in dollars (in thousands):

| Operating expenses:        |     | Three Months    
 Ended March 31, 
 2025            |      |   |     | 2024 |        |   |     | Change |      |   |
|:---------------------------|:----|:----------------|-----:|:--|:----|:-----|-------:|:--|:----|:-------|-----:|:--|
| Research and development   |     | $               |  187 |   |     | $    |    931 |   |     | $      | (744 | ) |
| General and administrative |     |                 |  478 |   |     |      |    575 |   |     |        |  (97 | ) |
| Total operating expenses   |     |                 |  665 |   |     |      |  1,506 |   |     |        | (841 | ) |
| Loss from operations       |     |                 | (665 | ) |     |      | (1,506 | ) |     |        |  841 |   |
| Net loss                   |     | $               | (665 | ) |     | $    | (1,506 | ) |     | $      |  841 |   |

|                            |     | Year Ended   
 December 31, |   2024 |   |     |   |   2023 |   |     |   | Change |   |
|:---------------------------|:----|:-------------|-------:|:--|:----|:--|-------:|:--|:----|:--|-------:|:--|
| Operating expenses:        |     |              |        |   |     |   |        |   |     |   |        |   |
| Research and development   |     | $            |  1,709 |   |     | $ |  1,621 |